[{"arm_notes": "", "treatment_id": null, "treatment_name": "Current interventions as of 03/06/2021: The study is a double-blind; randomised; placebo-controlled trial that will be conducted primarily in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other persons at risk of contracting COVID-19; who can be followed reliably for 5 months. The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation); or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10mg base/kg (four 155 mg tablets for a 60 kg subject); followed by 155 mg daily (250 mg chloroquine phosphate salt/ 200 mg hydroxychloroquine sulphate) will be taken for 3 months. A randomisation list will be prepared by a statistician using block randomisation in a 1:1 ratio for the chloroquine/ hydroxychloroquine arm versus the placebo and stratified by site. The randomisation will be computer-generated and programmed in Stata 15. Previous interventions: The study will be conducted in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other staff working in a facility where there are cases of either proven; or suspected COVID-19; who can be followed reliably for 5 months. The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation); or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10 mg base/kg (between three and five tablets e.g.; four 155-mg tablets for a 60-kg subject); followed by 155 mg daily (250 mg chloroquine phosphate salt/200 mg hydroxychloroquine sulphate) will be taken for 3 months.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 279, "treatment_name": "Chloroquine", "treatment_type": "Antimalarials", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 607, "treatment_name": "Hydroxychloroquine", "treatment_type": "Antimalarials", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Current interventions as of 03/06/2021: The study is a double-blind; randomised; placebo-controlled trial that will be conducted primarily in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other persons at risk of contracting COVID-19; who can be followed reliably for 5 months. The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation); or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10mg base/kg (four 155 mg tablets for a 60 kg subject); followed by 155 mg daily (250 mg chloroquine phosphate salt/ 200 mg hydroxychloroquine sulphate) will be taken for 3 months. A randomisation list will be prepared by a statistician using block randomisation in a 1:1 ratio for the chloroquine/ hydroxychloroquine arm versus the placebo and stratified by site. The randomisation will be computer-generated and programmed in Stata 15. Previous interventions: The study will be conducted in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other staff working in a facility where there are cases of either proven; or suspected COVID-19; who can be followed reliably for 5 months. The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation); or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10 mg base/kg (between three and five tablets e.g.; four 155-mg tablets for a 60-kg subject); followed by 155 mg daily (250 mg chloroquine phosphate salt/200 mg hydroxychloroquine sulphate) will be taken for 3 months.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "The study will be conducted in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other staff working in a facility where there are cases of either proven; or suspected COVID-19; who can be followed reliably for 5 months. The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation); or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10 mg base/kg (between three and five tablets e.g.; four 155-mg tablets for a 60-kg subject); followed by 155 mg daily (250 mg chloroquine phosphate salt/200 mg hydroxychloroquine sulphate) will be taken for 3 months. A randomisation list will be prepared by a statistician using block randomisation in a 1:1 ratio for the chloroquine/ hydroxychloroquine arm versus the placebo and stratified by site. The randomisation will be computer-generated and programmed in Stata 15.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]